This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.
Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.
ASCVD Playbook | Closing the Gaps, One Inning at a Time
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
J.A. Randy Englert, MD, FACC
Non-invasive Cardiologist
Ochsner Health
New Orleans, LA
Advisor/consultant: Amgen, Novartis
Matthew Malachowski, Pharm. D., MHA
System AVP
Ochsner Health
New Orleans, LA
Dr. Malachowski has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Wilma Guerra, MD has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify and stratify patients at high risk of atherosclerotic cardiovascular disease (ASCVD), including underserved and nontraditional phenotypes, using evidence-based approaches
- Apply LDL-C–centered, evidence-based strategies for treatment intensification and long-term lipid management
- Implement systems-based secondary prevention and shared decision-making strategies to improve outcomes and access
Target Audience
This activity has been designed to meet the educational needs of cardiologists and family medicine physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with ASCVD.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this MinuteCE activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 hour(s)/.075 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-064-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until 06/08/2027. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
